Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Bavarian Nordic A/S    BAVA   DK0015998017

BAVARIAN NORDIC A/S (BAVA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
223.1(c) 225.1(c) 225.5(c) 232(c) 245.5(c) Last
184 449 265 583 248 734 422 366 537 386 Volume
+0.54% +0.90% +0.18% +2.88% +5.82% Change
More quotes
Financials ( DKK)
Sales 2017 1 295 M
EBIT 2017 371 M
Net income 2017 289 M
Finance 2017 1 986 M
Yield 2017 -
Sales 2018 921 M
EBIT 2018 26,7 M
Net income 2018 115 M
Finance 2018 1 856 M
Yield 2018 -
P/E ratio 2017 26,29
P/E ratio 2018 64,70
EV / Sales2017 4,24x
EV / Sales2018 6,11x
Capitalization 7 481 M
More Financials
Company
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.The company operates its business through the cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast,... 
Sector
Pharmaceuticals
Calendar
03/12Earnings Release
More about the company
Surperformance© ratings of Bavarian Nordic A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on BAVARIAN NORDIC A/S
01/19 BAVARIAN NORDIC A/S : Announces Initiation of Clinical Trial with Novel Cancer I..
01/05 BAVARIAN NORDIC A/S : - Articles of Association
2017 BAVARIAN NORDIC A/S : Announces Exercise of Clinical Option by the US Government..
2017 BAVARIAN NORDIC A/S : Capital Increase in Bavarian Nordic AS as a Result of Empl..
2017 BAVARIAN NORDIC A/S : - Articles of Association
2017 BAVARIAN NORDIC A/S : Capital Increase in Bavarian Nordic A/S as a Result of Emp..
2017 BAVARIAN NORDIC A/S : Announces Exercise of Clinical Option by the US Government..
2017 BAVARIAN NORDIC A/S : Announces Interim Results for the First Nine Months of 201..
2017 BAVARIAN NORDIC A/S : Announces Initiation of Phase 2 Booster Study of its Unive..
2017 BAVARIAN NORDIC A/S : Announces Interim Results for the First Nine Months of 201..
More news
Sector news : Pharmaceuticals - NEC
09:20a BIOVERATIV : Sanofi shares fall on $11.6 billion Bioverativ takeover
08:48a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
08:48a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
08:48a SANOFI : Nears Deal for Bioverativ -- WSJ
08:47a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/19Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immu.. 
01/19Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immu.. 
2017Global Biodefense Market 2017-2021 - Key Vendors are Altimmune, Bavarian Nord.. 
2017Global Biodefense Market 2017-2021 - Key Vendors are Altimmune, Bavarian Nord.. 
2017Bavarian Nordic downgraded by Zacks Investment Research to sell.  
More tweets
Qtime:42
News from SeekingAlpha
2017 Bavarian Nordic's (BVNKF) CEO Paul Chaplin on Q3 2017 Results - Earnings Call..
2017 Bavarian Nordic A/S 2017 Q3 - Results - Earnings Call Slides
2017 Bavarian Nordic A/S reports Q3 results
2017 Bavarian Nordic (BVNRY) New Barda Contract For Freeze-Dried Imvamune - Slides..
2017 Bavarian Nordic (BVNRY) Investor Presentation - Slideshow
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | BAVA | DK0015998017 | 4-Traders
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 308  DKK
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Paul Chaplin President & Chief Executive Officer
Gerardus Wilhelmus van Odijk Chairman
Henrik Birk Chief Operating Officer & Executive Vice President
Ole Larsen Chief Financial Officer & Executive Vice President
Christopher R. Heery Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAVARIAN NORDIC A/S3.43%1 229
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132